Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2025. The report serves to disclose a specific corporate governance event: the appointment of Dr. Gavin Screaton to the Board of Directors, effective May 1, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding a director appointment and does not contain financial performance data.
Material Changes
The primary material change disclosed is the addition of Dr. Gavin Screaton to the Board. Upon joining, Dr. Screaton holds 8,675 ordinary shares of 31 pence each in the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It strictly confirms the directorate change and shareholding status.
Investor Verification Checklist
- Verify the official announcement of Dr. Gavin Screaton's appointment on the London Stock Exchange (Reference: 16909060).
- Confirm the shareholding count of 8,675 ordinary shares held by the new director.
- Review the company's latest Form 20-F for comprehensive financial metrics, as this 6-K does not include them.